Similarly, the NCI-MATCH trial revealed restricted effectiveness of AZD4547 in refractory cancers exhibiting FGFR1-3 aberrations, with responses observed solely in tumors harboring FGFR1-3 point mutations or fusions [133]. Here, FGFR1 is linked to cancer.